These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
110 related articles for article (PubMed ID: 685778)
1. Review of marketed drugs in the United Kingdom. Cuthbert MF; Cone MD Agents Actions; 1978 Jun; 8(4):412-3. PubMed ID: 685778 [No Abstract] [Full Text] [Related]
2. Post-marketing surveillance of adverse reactions to new medicines. Wilson AB Br Med J; 1977 Oct; 2(6093):1001-3. PubMed ID: 922357 [No Abstract] [Full Text] [Related]
3. Symposium on drug safety. The role of regulatory agencies and industry in assessment of the safety of drugs for use in man. The situation in the United Kingdom. Cahal DA Can Med Assoc J; 1968 Feb; 98(6):271-5. PubMed ID: 5636096 [No Abstract] [Full Text] [Related]
4. Present attitudes of governmental drug regulatory agencies. Noel PR Int J Clin Pharmacol; 1973 Apr; 7(2):168-77. PubMed ID: 4731283 [No Abstract] [Full Text] [Related]
5. [Pharmacovigilance in the framework of recording and control of drugs in the United Kingdom]. Dunlop D Therapie; 1974; 29(6):799-804. PubMed ID: 4462229 [No Abstract] [Full Text] [Related]
7. Monitoring of adverse reactions to drugs in the United Kingdom. Inman WH Proc R Soc Med; 1970 Dec; 63(12):1302-4. PubMed ID: 5490790 [No Abstract] [Full Text] [Related]
8. Clinical pharmacology in the United Kingdom. Smith RN Clin Pharmacol Ther; 1974 Sep; 16(3):605-15. PubMed ID: 4412474 [No Abstract] [Full Text] [Related]
9. Review of marketed medicinal products: review procedures in Finland and Norway. Idänpään-Heikkilä J Agents Actions; 1978 Jun; 8(4):414-7. PubMed ID: 98975 [No Abstract] [Full Text] [Related]
10. Control of new drugs in the United Kingdom. Cuthbert MF Agents Actions; 1978 Jun; 8(4):410-2. PubMed ID: 685777 [No Abstract] [Full Text] [Related]
11. Evaluation of spontaneous reports of adverse reactions to drugs. Inman WH; Evans DA Br Med J; 1972 Sep; 3(5829):746-9. PubMed ID: 5077919 [TBL] [Abstract][Full Text] [Related]
12. Clinical pharmacology. Drug monitoring. Moir DC Br Med J (Clin Res Ed); 1981 Feb; 282(6264):632-4. PubMed ID: 6781602 [No Abstract] [Full Text] [Related]
13. The safety of new drugs. Hull CJ Br J Anaesth; 1989 Jun; 62(6):587-9. PubMed ID: 2751914 [No Abstract] [Full Text] [Related]
14. Review of marketed medicinal products: review procedures in Holland and Benelux. Dukes MN Agents Actions; 1978 Jun; 8(4):414. PubMed ID: 685779 [No Abstract] [Full Text] [Related]
15. Discussion on control of new drugs. Practitioner; 1971 Apr; 206(234):546-50. PubMed ID: 4930721 [No Abstract] [Full Text] [Related]
17. Identification of adverse reactions to new drugs. II (continued): How were 18 important adverse reactions discovered and with what delays? Venning GR Br Med J (Clin Res Ed); 1983 Jan; 286(6362):365-8. PubMed ID: 6402104 [No Abstract] [Full Text] [Related]
18. Adverse drug reactions: definition of the problem. Dunlop D Am J Epidemiol; 1971 Nov; 94(5):403-4. PubMed ID: 5120537 [No Abstract] [Full Text] [Related]
19. [Intensified drug control--with drawbacks?]. Böttiger LE Lakartidningen; 1983 Feb; 80(7):575-81. PubMed ID: 6855371 [No Abstract] [Full Text] [Related]
20. Drugs: their uses and abuses, and the problem of their control. Dunlop D Vet Rec; 1969 Oct; 85(16):424-9. PubMed ID: 5387898 [No Abstract] [Full Text] [Related] [Next] [New Search]